Among patients with HER2‐positive early breast cancer following NAT, those with a lower N stage had a better DFS (log‐rank p = 0.001), and those with a higher MP grade had a better DFS (log‐rank p < 0.001). The gene discussed is ERBB2; the disease is breast cancer.